Previous 10 | Next 10 |
Aduro Biotech ( ADRO -42.2% ) slumps on a 4x surge in volume in response to data presented at ASCO on STING candidate ADU-S100. More news on: Aduro BioTech, Inc., Novartis AG, Synlogic, Inc., Healthcare stocks news, Stocks on the move, Read more ...
TORONTO, May 13, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial results for the three months ended March 31, 2019. “We are cont...
Takeda Pharmaceutical (NYSE: TAK ) inks an agreement with privately held Curadev for the rights to CRD5500, its lead small molecule Stimulator of Interferon Genes (STING) agonist for the potential treatment of solid tumors. More news on: Takeda Pharmaceutical Company Limited, Tril...
TORONTO, April 30, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announces changes to its executive man...
TORONTO, April 15, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the publication of data highlighting the role of TTI-621 in treating patients wi...
TORONTO, April 11, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL) , a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has received a notification letter from The Nasdaq Stock Market LLC ("Na...
The following slide deck was published by Trillium Therapeutics Inc. in conjunction with this Read more ...
TORONTO, April 08, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company’s progr...
Trillium Therapeutics ( TRIL -4.4% ) has added a STING (stimulator of interferon genes) agonist program to its pipeline named TTI-10001, a development that apparently lacks investor enthusiasm. More news on: Trillium Therapeutics Inc., Merck & Co., Inc., Bristol-Myers Squibb Compan...
TORONTO, April 02, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (Nasdaq/TSX: TRIL), a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has expanded its immuno-oncology pipeline with a STING agonist program a...
News, Short Squeeze, Breakout and More Instantly...
Trillium Therapeutics Inc. Company Name:
TRIL Stock Symbol:
NASDAQ Market:
Trillium Therapeutics Inc. Website:
The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substance...
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributors Keith Speights and Brian Orelli explain why the news of a discontinued drug from the pharmaceutical giant hasn't shaken investors. Keith Speights: Pf...
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL) , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to announce...